We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesViking Therapeutics Inc

Viking Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
27.75 USD -0.69 ( 2.43%)
Last update at 2026-11-12T15:17:00Z
VOLUME
486004
Market Cap
6973.35M

Momentum Score

…

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
27.49
Low
28.24
High
52 Week Price Range
8.28
Low
99.41
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
28.44
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-17.55%
Net Debt
-54.26M
ROCE
-28.86%
Diluted EPS TTM
-0.92

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -85.89M -68.87M -54.99M -39.49M -25.78M
Net income -85.89M -67.38M -54.00M -39.49M -25.78M
Selling general administrative 37.02M 16.12M 10.70M 10.73M 9.13M
Selling and marketing expenses 0.29M - - - -
Gross profit -0.29M -0.29M -0.30M 0.01M -0.26M
Reconciled depreciation 0.29M 0.29M 0.30M 0.28M 0.26M
Ebit -100.83M -70.36M -55.68M -39.49M -32.69M
Ebitda -100.83M -70.31M -55.69M 3.77M -25.52M
Depreciation and amortization 0.29M 0.04M -0.01M 3.81M 7.16M
Non operating income net other - 1.23M 0.69M 3.17M 6.91M
Operating income -100.83M -70.36M -55.68M -42.66M -32.69M
Other operating expenses 100.83M 70.36M 55.68M 42.66M 32.69M
Interest expense 0.09M 1.49M 0.02M 0.11M 0.15M
Interest income 11.05M 1.59M 0.70M 3.23M 7.05M
Net interest income 10.98M 1.53M 0.69M 3.13M 6.90M
Income tax expense - -1.49M -0.99M -3.48M -0.00M
Total revenue 0.00M 0.00M 0.01M 0.01M 0.00M
Total operating expenses 100.83M 70.36M 55.68M 42.66M 32.69M
Cost of revenue 0.29M 0.29M 0.30M 0.28M 0.26M
Total other income expense net 14.93M 1.49M 0.69M 42.62M 6.91M
Net income from continuing ops -80.85M -69.12M -54.99M -39.49M -25.78M
Net income applicable to common shares - -68.87M -54.99M -39.49M -25.78M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 368.49M 168.53M 210.66M 256.50M 284.26M
Other current assets 2.52M 3.41M 8.43M 7.72M 7.86M
Total liab 20.07M 23.21M 8.78M 12.16M 7.14M
Total stockholder equity 348.42M 145.32M 201.88M 244.34M 277.12M
Deferred long term liab - 0.04M 0.08M 0.05M 0.13M
Other current liab 11.30M 13.11M 7.30M 7.81M 4.04M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -377.94M -292.05M -223.18M -168.19M -128.70M
Other assets - 0.07M 0.11M 0.40M 0.16M
Cash 55.52M 36.63M 26.37M 29.12M 8.38M
Total current liabilities 19.14M 21.95M 8.78M 12.13M 6.78M
Net debt -54.26M -35.07M -26.34M -28.76M -7.71M
Short term debt 0.32M 0.30M 0.03M 0.33M 0.30M
Short long term debt total 1.26M 1.56M 0.03M 0.36M 0.66M
Other stockholder equity 726.75M 438.47M 425.61M 412.59M 405.80M
Property plant equipment - 1.42M 0.03M 0.32M 0.60M
Total current assets 367.23M 167.04M 210.53M 256.10M 283.50M
Net tangible assets - 145.32M 201.88M 244.34M 277.12M
Short term investments 306.56M 118.85M 175.73M 219.27M 267.26M
Accounts payable 7.51M 8.53M 1.44M 3.99M 2.43M
Accumulated other comprehensive income -0.39M -1.10M -0.55M -0.05M 0.01M
Common stock total equity - 0.00M 0.00M 0.00M 0.00M
Retained earnings total equity - -292.05M -223.18M -168.19M -128.70M
Treasury stock - -6.79M - - -
Non currrent assets other 0.14M 0.07M 0.11M 0.08M 0.16M
Non current assets total 1.26M 1.49M 0.13M 0.40M 0.76M
Capital lease obligations 1.26M 1.56M 0.03M 0.36M 0.66M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -207.56M 54.75M 37.96M 41.57M 7.46M
Change to liabilities - 12.89M -3.05M 5.32M 3.87M
Total cashflows from investing activities - 54.75M 37.96M 41.57M 7.46M
Total cash from financing activities 271.38M 4.16M 6.88M 0.95M 0.89M
Change to operating activities - 3.10M -0.38M 6.16M -5.25M
Net income -85.89M -68.87M -54.99M -39.49M -25.78M
Change in cash 18.88M 10.26M -2.75M 20.74M -16.40M
Begin period cash flow 36.63M 26.37M 29.12M 8.38M 24.78M
End period cash flow 55.52M 36.63M 26.37M 29.12M 8.38M
Total cash from operating activities -73.38M -48.40M -47.59M -21.78M -24.75M
Issuance of capital stock - - - - 0.00M
Depreciation 0.29M 0.29M 0.30M 0.28M 0.26M
Other cashflows from investing activities - - - - 7.46M
Change to account receivables - - - 0.00M -
Sale purchase of stock -0.01M -6.79M -0.00M -0.00M -0.00M
Other cashflows from financing activities -5.15M 10.13M -0.71M -0.30M -0.15M
Change to netincome - 8.67M 6.10M 5.82M 3.74M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Cash flows other operating - -2.31M 0.45M 2.77M -7.06M
Cash and cash equivalents changes - 10.52M -2.75M 20.74M -16.40M
Change in working capital 3.55M 10.19M -2.93M 7.72M -3.78M
Stock based compensation 16.75M 8.67M 6.10M 5.82M 3.74M
Other non cash items 0.13M 1.32M 0.03M 0.14M 0.33M
Free cash flow -73.38M -48.40M -47.59M -21.78M -24.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
VKTX
Viking Therapeutics Inc		 -0.69
2.43%		 27.75 - - - 21.71 -71.64
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121

858 704 4660

https://www.vikingtherapeutics.com

28

Name Title Year Born
Dr. Brian Lian Ph.D. Pres, CEO & Director 1966
Mr. Gregory S. Zante Chief Financial Officer 1971
Ms. Marianne Mancini Chief Operating Officer 1965
Mr. Michael Morneau VP of Fin. & Admin. 1965
Dr. Brian Lian Ph.D. President, CEO & Director 1966
Mr. Michael Morneau Vice President of Finance & Administration 1965
Dr. Geoffrey E. Barker Ph.D. Senior Vice President of Pharmaceutical Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…